A study to assess the effect of oral belumosudil on inhibition of various proteins in the fed state in healthy male subjects

Trial Identifier: INT17676
Sponsor: Kadmon, a Sanofi Company
Start Date: July 2022
Primary Completion Date: October 2022
Study Completion Date: October 2022
Condition: Immune, Inflammatory & Infections - Other; Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, Florida Miami, Florida, United States, 33126